Kenvue (KVUE) is mulling the sale of some of its skin health and beauty brands as the management looks to prune some of its underperforming business assets to focus on core products, Reuters reports, citing people familiar with the matter. Kenvue plans to hold onto the bigger names, such as Neutrogena and Aveeno, the report states.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue Inc call volume above normal and directionally bullish
- Positive Outlook for Kenvue, Inc.: Stability Amid Challenges and Growth Opportunities
- Strategic Expansion of Kenvue, Inc. into the Supplements Market with Tylenol Brand
- Kenvue Inc. Shareholders Approve Key Proposals at 2025 Meeting
- Kenvue Inc. Completes $750 Million Senior Notes Offering